// App-Quantinova.ai

TCT-164 : Targeted Therapy With a Localized Abluminal Groove Low-Dose Sirolimus-Eluting Biodegradable-Polymer Coronary Stent: Subgroup Analysis of 5-Year Outcomes of the TARGET All Comers Randomized Trial

Researchers

Presenter

  • Henning Kelbæk

Principal Investigators

  • Alexandra Lansky

  • Bo Xu

  • Andreas Baumbach

  • Niels van Royen

  • Paul Knaapen

  • Thomas Johnson

  • Pieter Smits

  • Georgios Vlachojannis

  • Karin Arkenbout

  • Lene Holmvang

  • Luc Janssens

  • Andrzej Ochala

  • William Wijns

Medical Centers

  • Radboud University Medical Center, Njmegen, Netherlands

  • Amsterdam University Medical Center – Academic Medical Center, Amsterdam, the Netherlands

  • Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom

  • Yale School of Medicine, New Haven, Connecticut, USA

  • University Hospital, Katowice, Poland

  • Department of Cardiology, Tergooi Hospital, Blaricum, the Netherlands

  • Cheltenham General Hospital, Auckland, New Zealand

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing, China

  • Maasstad Ziekenhuis, Rotterdam, the Netherlands

  • Rigshospitalet, Copenhagen, Denmark

  • Imelda Hospital Bonheiden, Bonheiden, Belgium

  • Lambe Institute for Translational Medicine and CURAM, National University of Ireland Galway, Galway, Ireland

  • Roskilde Hospital, Roskilde, Denmark

Locations

  • Netherlands

  • United Kingdom

  • United States

  • Poland

  • New Zealand

  • China

  • Denmark

  • Belgium

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

  • Rapacan

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Non Inferiority

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved